Merck Sharp + Dohme Corp.

Merck + Co., Inc.

Merck Canada Inc.

Merck Frosst Canada, Inc.

Merck Frosst Canada & Co.

Kaneq Pharma Inc.

Iomet Pharma Ltd.

Msd Italia S.r.l.

Merch Sharp & Dohme Ltd

Merk Frosst Canada & Co.

Yongxin Han

Xavier Fradera

Hongjun Zhang

Wensheng Yu

John Colucci

Hua Zhou

Derun Li

Kun Liu

Shuwen He

Liangqin Guo

Nunzio Sciammetta

Abdelghani Achab

Meredeth Ann McGowan

David L Sloman

Alexander Pasternak

Christopher I Bayly

Qinglin Pu

Robert N Young

Dane James Clausen

Joseph A Kozlowski

Li Xiao

Yongqi Deng

Catherine M White

Jongwon Lim

Michel L Belley

Claude Dufresne

David Jonathan Bennett

Nigel J Liverton

Xianhai Huang

Cheuk K Lau

Phieng Siliphaivanh

Michael T Rudd

Cameron Black

Guoqing Li

Erich L Grimm

Jason Burch

Kerrie Spencer

Anandan Palani

Robert J Zamboni

Shawn J Stachel

Thomas H Graham

Petpiboon Prasit

Ryan D Otte

Ping Chen

Timothy J Henderson

Craig R Gibeau

Paul Tempest

Zhaoyang Meng

Phillip Martin Cowley

Feng Ye

Samuel Chackalamannil

Zhaoyin Wang

Srikanth Venkatraman

Yunfu Luo

Serge Leger

Chun Sing Li

Pierre A Hamel

Purakkattle J Biju

Claudio F Sturino

Kenneth L Arrington

Francisco Velazquez

Unmesh G Shah

Mehul F Patel

Michael Boyd

Alan Wise

Ravi P Nargund

Duane A Burnett

Hubert B Josien

John A McCauley

Ashok Arasappan

Dong Xiao

Robert S Meissner

Robert R Wilkening

Yan Xia

James J Perkins

Christopher S Burgey

Iyassu Sebhat

Vincenzo Summa

Marco Ferrara

Zhi-Cai Shi

Patrick A Pinto

Zhuyan Guo

Peter J Manley

Santhosh Francis Neelamkavil

Mariappan Chelliah

Linda Brockunier

Shouwu Miao

Steven Harper

Christopher James Bungard

Scott B Hoyt

Kenneth J Leavitt

Jessica Frie

Martin C Clasby

Min Lu

Marc Blouin

Carl Berthelette

Benoit Bachand

Thomas A Bara

Sathesh P Bhat

Austin Chen

The disclosure provides compounds of Formula (I) or a pharmaceutically acceptable salt thereof, wherein W, W, Y, Z, M, L, C, C, R, R, R, R, R, R, R, and the subscripts m, n, q, and r are as described herein. The compounds or their pharmaceutically acceptable salts can inhibit the G12C mutant of Kirsten rat sarcoma (KRAS) protein and are expected to have utility as therapeutic agents, for example, for treating cancer. The disclosure also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.

Small molecule inhibitors of KRAS G12C mutant

Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof (I). Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

Substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are antagonists of leukotriene Breceptor 1 (BLT1) and may be useful in the treatment, prevention and suppression of diseases mediated by the leukotriene Breceptor 1 (BLT1). The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, insulin resistance, hyperglycemia, dyslipidemia, lipid disorders, obesity, hypertension, Nonalcoholic fatty liver disease/nonalcoholic steatohepatitis, metabolic syndrome, atherosclerosis, and cancer.

Aryl sulfonamides as BLT1 antagonists

Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

Substituted piperazine amide compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors

Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

Arylalkyl pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors

Substituted pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors

Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: Formula (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

Substituted tricyclic compounds as indoleamine 2,3-dioxygenase inhibitors

Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

Substituted tetrahydroquinoline compounds as indoleamine 2,3-dioxygenase inhibitors

The disclosure provides compounds of Formula (I) or a pharmaceutically acceptable salt thereof, wherein W, W, Y, Z, M, L, C, C, R, R, R, R, R, R, Rand the subscripts m, n, q, and r are as described herein. The compounds or their pharmaceutically acceptable salts can inhibit the G12C mutant of Kirsten rat sarcoma (KRAS) protein and are expected to have utility as therapeutic agents, for example, for treating cancer. The disclosure also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.

In its many embodiments, the present invention provides certain substituted aryl and heteroaryl ether compounds of the Formula (I): and pharmaceutically acceptable salts thereof, wherein X, R, R, R, L, R, L, Q, and Rare as defined herein. The novel compounds of the invention, and pharmaceutically acceptable compositions comprising a compound thereof, are useful as Liver X-&#x3b2; receptor (LXR&#x3b2;) agonists, and may be useful for treating or preventing pathologies related thereto. Such pathologies include, but are not limited to, inflammatory diseases and diseases characterized by defects in cholesterol and lipid metabolism, such as Alzheimer's disease. 

Aryl and heteroaryl ether derivatives as liver X receptor beta agonists, compositions, and their use

Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof. Also disclosed herein are uses of a compound disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of a composition in the potential treatment or prevention of an IDO-associated disease or disorder. 

Substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors

Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder. 

[1.1.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors

Substituted [1.1.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors

Growing community of inventors

Needham, MA, United States of America

Yongxin Han